Ligand is developing a novel Captisol®-based formulation of Busulfan for use as a conditioning agent prior to hematopoietic stem cell transplantation. Captisol Enabled™ Busulfan is designed to remove the toxic excipients N,N-dimethylacetamide (DMA) and polyethylene glycol (PEG), which are present in the marketed product IV BUSULFEX® (busulfan). Captisol Enabled™ Busulfan has the potential to improve tolerance, which may result in higher drug exposure and longer duration of therapy.
